Combination therapy for the treatment of pulmonary arterial hypertension

Therapeutic Advances in Respiratory Disease

Volumn 5, Issue 6, 2011, Pages 419-430

  Levinson, Andrew T ^a,b   Klinger, James R ^a,b  

^a RHODE ISLAND HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

combination therapy; pulmonary arterial hypertension; pulmonary hypertension treatment

Indexed keywords

BERAPROST; BOSENTAN; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; ILOPROST; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; SILDENAFIL; TADALAFIL; UNIPROST;

COMBINATION CHEMOTHERAPY; HEMODYNAMICS; HUMAN; LUNG VASCULAR RESISTANCE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW;

ANIMALS; ANTIHYPERTENSIVE AGENTS; DISEASE PROGRESSION; DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION, PULMONARY; TREATMENT OUTCOME;

EID: 83455230686     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465811411602     Document Type: Review

References (34)

1. Badesch D.B. Champion H.C. Sanchez M.A. Hoeper M.M. Loyd J.E. Manes A. (2009) Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 54(1 Suppl): S55's66.
2. Barst R.J. Rubin L.J. Long W.A. McGoon M.D. Rich S. Badesch D.B. (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 334: 296–302.
3. Benza R.L. Gupta H. Soto F.J. Park M.H. Torres F. Frey N. Murali S. (2010) Safety and efficacy of bosentan in combination with sildenafil in PAH patients who experience inadequate clinical response to monotherapy: The COMPASS-3 Study. Chest 138: 840 A.
4. Boulanger C. Luscher T.F. (1990) Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest 85: 587–590.
5. Charloux A. Chaouat A. Piquard F. Brandenberger G. Weitzenblum E. Geny B. (2006) Renal hyporesponsiveness to brain natriuretic peptide: both generation and renal activity of cGMP are decreased in patients with pulmonary hypertension. Peptides 27: 2993–2999.
6. Christman B.W. McPherson C.D. Newman J.H. King G.A. Bernard G.R. Groves B.M. (1992) An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327: 70–75.
7. Emori T. Hirata Y. Imai T. Eguchi S. Kanno K. Marumo F. (1993) Cellular mechanism of natriuretic peptides-induced inhibition of endothelin-1 biosynthesis in rat endothelial cells. Endocrinology 133: 2474–2480.
8. Galie N. Brundage B.H. Ghofrani H.A. Oudiz R.J. Simonneau G. Safdar Z. (2009) Tadalafil therapy for pulmonary arterial hypertension. Circulation 119: 2894–2903.
9. Galie N. Ghofrani H.A. Torbicki A. Barst R.J. Rubin L.J. Badesch D. (2005) Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353: 2148–2157.
10. Galie N. Olschewski H. Oudiz R.J. Torres F. Frost A. Ghofrani H.A. (2008) Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 117: 3010–3019.
11. Ghofrani H.A. Rose F. Schermuly R.T. Olschewski H. Wiedemann R. Kreckel A. (2003) Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 42: 158–164.
12. Ghofrani H.A. Wiedemann R. Rose F. Olschewski H. Schermuly R.T. Weissmann N. (2002) Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 136: 515–522.
13. Giaid A. Saleh D. (1995) Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 333: 214–221.
14. Giaid A. Yanagisawa M. Langleben D. Michel R.P. Levy R. Shennib H. (1993) Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328: 1732–1739.
15. Hanson K.A. Ziegler J.W. Rybalkin S.D. Miller J.W. Abman S.H. Clarke W.R. (1998) Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity. Am J Physiol 275(5 Pt 1): L931–L941.
16. Hoeper M.M. Faulenbach C. Golpon H. Winkler J. Welte T. Niedermeyer J. (2004) Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 24: 1007–1010.
17. Hoeper M.M. Leuchte H. Halank M. Wilkens H. Meyer F.J. Seyfarth H.J. (2006) Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 28: 691–694.
18. Humbert M. Barst R.J. Robbins I.M. Channick R.N. Galie N. Boonstra A. (2004) Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 24: 353–359.
19. Ikeda D. Tsujino I. Ohira H. Itoh N. Kamigaki M. Ishimaru S. (2005) Addition of oral sildenafil to beraprost is a safe and effective therapeutic option for patients with pulmonary hypertension. J Cardiovasc Pharmacol 45: 286–289.
20. Itoh T. Nagaya N. Fujii T. Iwase T. Nakanishi N. Hamada K. (2004) A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats. Am J Respir Crit Care Med 169: 34–38.
21. Kharitonov S.A. Cailes J.B. Black C.M. du Bois R.M. Barnes P.J. (1997) Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension. Thorax 52: 1051–1055.
22. McLaughlin V.V. Benza R.L. Rubin L.J. Channick R.N. Voswinckel R. Tapson V.F. (2010) Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 55: 1915–1922.
23. McLaughlin V.V. Oudiz R.J. Frost A. Tapson V.F. Murali S. Channick R.N. (2006) Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 174: 1257–1263.
24. Moncada S. Gryglewski R. Bunting S. Vane J.R. (1976) An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263: 663–665.
25. Nagaya N. Nishikimi T. Uematsu M. Satoh T. Kyotani S. Sakamaki F. (2000) Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102: 865–870.
26. Nagendran J. Archer S.L. Soliman D. Gurtu V. Moudgil R. Haromy A. (2007) Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 116: 238–248.
27. Rubens C. Ewert R. Halank M. Wensel R. Orzechowski H.D. Schultheiss H.P. (2001) Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 120: 1562–1569.
28. Rubin L.J. Badesch D.B. Barst R.J. Galie N. Black C.M. Keogh A. (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346: 896–903.
29. Seyfarth H.J. Pankau H. Hammerschmidt S. Schauer J. Wirtz H. Winkler J. (2005) Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy. Chest 128: 709–713.
30. Simonneau G. Robbins I.M. Beghetti M. Channick R.N. Delcroix M. Denton C.P. (2009) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54(1 Suppl): S43's54.
31. Simonneau G. Rubin L.J. Galie N. Barst R.J. Fleming T.R. Frost A.E. (2008) Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 149: 521–530.
32. Stewart D.J. Levy R.D. Cernacek P. Langleben D. (1991) Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?. Ann Intern Med 114: 464–469.
33. Tuder R.M. Cool C.D. Geraci M.W. Wang J. Abman S.H. Wright L. (1999) Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 159(6): 1925–1932.
34. Xu W. Kaneko F.T. Zheng S. Comhair S.A. Janocha A.J. Goggans T. (2004) Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. FASEB J 18: 1746–1748.